Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabis-associated psychosis: Neural substrate and clinical impact
Robin M. Murray, Amir Englund, Anissa Abi‐Dargham, et al.
Neuropharmacology (2017) Vol. 124, pp. 89-104
Closed Access | Times Cited: 177

Showing 1-25 of 177 citing articles:

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
Marta Di Forti, Diego Quattrone, Tom P. Freeman, et al.
The Lancet Psychiatry (2019) Vol. 6, Iss. 5, pp. 427-436
Open Access | Times Cited: 707
Cannabis Use and the Risk for Psychosis and Affective Disorders
Lucia Sideli, Harriet Quigley, Caterina La Cascia, et al.
Journal of Dual Diagnosis (2019) Vol. 16, Iss. 1, pp. 22-42
Closed Access | Times Cited: 109
Heavy cannabis use, dependence and the brain: a clinical perspective
Emese Kroon, Lauren Kuhns, Eva Hoch, et al.
Addiction (2019) Vol. 115, Iss. 3, pp. 559-572
Open Access | Times Cited: 101
Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review
Deborah S. Hasin, Claire Walsh
Journal of Clinical Medicine (2020) Vol. 10, Iss. 1, pp. 15-15
Open Access | Times Cited: 85
Gene-Environment Interactions in Schizophrenia: A Literature Review
Marah H. Wahbeh, Dimitrios Avramopoulos
Genes (2021) Vol. 12, Iss. 12, pp. 1850-1850
Open Access | Times Cited: 85
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study
Diego Quattrone, Laura Ferraro, Giada Tripoli, et al.
Psychological Medicine (2020) Vol. 51, Iss. 8, pp. 1329-1337
Open Access | Times Cited: 70
Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy
Giulia Abate, Daniela Uberti, Simone Tambaro
Biology (2021) Vol. 10, Iss. 6, pp. 542-542
Open Access | Times Cited: 70
Substance-Induced Psychoses: An Updated Literature Review
A. Fiorentini, Filippo Cantù, Camilla Crisanti, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 67
Pharmacological effects of cannabidiol by transient receptor potential channels
Leila Etemad, Gholamreza Karimi, Mohaddeseh Sadat Alavi, et al.
Life Sciences (2022) Vol. 300, pp. 120582-120582
Closed Access | Times Cited: 44
THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
Nicholas Pintori, Francesca Caria, Maria Antonietta De Luca, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5251-5251
Open Access | Times Cited: 28
The Underlying Neurobiological Mechanisms of Psychosis: Focus on Neurotransmission Dysregulation, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction
Neha S. Rawani, Allen W. Chan, Serdar Dursun, et al.
Antioxidants (2024) Vol. 13, Iss. 6, pp. 709-709
Open Access | Times Cited: 10
The role of childhood trauma in cognitive performance in schizophrenia and bipolar disorder – A systematic review
Maria R. Dauvermann, Gary Donohoe
Schizophrenia Research Cognition (2018) Vol. 16, pp. 1-11
Open Access | Times Cited: 74
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
Albert Batalla, Hella Janssen, Shiral S. Gangadin, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 7, pp. 1058-1058
Open Access | Times Cited: 71
Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users
Camilla Beale, Samantha J. Broyd, Yann Chye, et al.
Cannabis and Cannabinoid Research (2018) Vol. 3, Iss. 1, pp. 94-107
Open Access | Times Cited: 68
The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression
Jairo Vinícius Pinto, Leonardo Simão Medeiros, Gabriel Santana da Rosa, et al.
Neuroscience & Biobehavioral Reviews (2019) Vol. 101, pp. 78-84
Closed Access | Times Cited: 62
Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study
Maureen A. Leehey, Ying Liu, Felecia Hart, et al.
Cannabis and Cannabinoid Research (2020) Vol. 5, Iss. 4, pp. 326-336
Open Access | Times Cited: 61
Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health
Justin Matheson, Bernard Le Foll
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 58
Advancing the science on cannabis concentrates and behavioural health
L. Cinnamon Bidwell, Renée Martin‐Willett, Hollis C. Karoly
Drug and Alcohol Review (2021) Vol. 40, Iss. 6, pp. 900-913
Open Access | Times Cited: 41
Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders
Marie‐Odile Krebs, Oussama Kébir, Thérèse M. Jay
European Journal of Pain (2019) Vol. 23, Iss. 7, pp. 1225-1233
Open Access | Times Cited: 49
Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition
Marco Colizzi, Mirella Ruggeri, Sagnik Bhattacharyya
Frontiers in Psychology (2020) Vol. 11
Open Access | Times Cited: 49
Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain
Caroline A. MacCallum, Lauren Eadie, Alasdair M. Barr, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 36
Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case–Control Analysis from the First Episode Case–Control EU-GEI WP2 Study: L’arrêt de l’utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l’étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiques
Brian Bond, Bea Duric, Edoardo Spinazzola, et al.
The Canadian Journal of Psychiatry (2025)
Closed Access
Links between psychotic and neurotic symptoms in the general population: an analysis of longitudinal British National Survey data using Directed Acyclic Graphs
Jack Kuipers, Giusi Moffa, E Kuipers, et al.
Psychological Medicine (2018) Vol. 49, Iss. 3, pp. 388-395
Open Access | Times Cited: 46
Genetic Predisposition vs Individual-Specific Processes in the Association Between Psychotic-like Experiences and Cannabis Use
Nicole R. Karcher, Deanna M. Barch, Catherine H. Demers, et al.
JAMA Psychiatry (2018) Vol. 76, Iss. 1, pp. 87-87
Open Access | Times Cited: 45
Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders
Musa Sami, Sagnik Bhattacharyya
Journal of Psychopharmacology (2018) Vol. 32, Iss. 8, pp. 825-849
Open Access | Times Cited: 44
Page 1 - Next Page

Scroll to top